Glyconics Ltd is an innovative diagnostics company which has developed a novel approach to the diagnosis and monitoring of chronic and acute diseases including respiratory disease. The new device uses fourier transform infrared spectroscopy (FITR) to analyse sputum (saliva) samples for specific biomarkers, characteristic of chronic obstructive pulmonary disease (COPD).
The team at Glyconics has been working to develop the new hand-held miniaturised device to be able to effectively diagnose and predict the exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in patients at the point of care. The Company’s aim is to optimise the hand-held, miniaturised FTIR device for easy detection of disease monitoring by healthcare workers at the point-of-care. The technology meets a clear medical need in the diagnosis, monitoring and clinical management of acute and chronic diseases.
In the UK in 2012, 29,776 people died from COPD, 2,719 were aged 15–64; 27,056 were aged 65 and above making it a predominately an age-related disease. Along with lung cancer and pneumonia, COPD is one of the three leading contributors to respiratory mortality in developed countries. (1.)
Examples of chronic COPD conditions include emphysema, chronic bronchitis and severe asthma.According to research carried out by Rightcare, NHS and ERPHO estimated that around 835,000 people in England are currently diagnosed with COPD and a further 2.2 million are undiagnosed (1).
The cost of treating COPD cost the NHS an estimated £1.2 billion per annum in 2010 (2.). COPD is the fifth biggest killer disease in the UK, killing approximately 25,000 people a year in England (3).
Glyconics Ltd plans to offer direct sales of the miniaturised IR device via the traditional medical distributor route for a retail price of £750 with the single use sputum disposable test selling at approximately £5 each. It is envisaged that the bulk of future recurring revenues will come from the repeat sale of the single use disposable test.